Browse News
Filter News
Found 10,954 articles
-
Now more than ever, there is ample opportunity for life science candidates with only a bachelor's degree. Still, there are certain things these candidates should know to ensure their success.
-
Costas, Inc. Year in Review (2022) and 2023 Business Strategy Report
1/31/2023
Costas, Inc. reviews 2022 Company milestones in the year following the December 2021 appointment of CEO and controlling shareholder, Mr. James Brooks.
-
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
1/31/2023
Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming General Meeting of Shareholders scheduled to be held on February 28, 2023.
-
EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal
1/31/2023
The completely unique mechanism of action of the world’s first COVID-19 vaccine to stimulate “high affinity” antibodies which neutralise most COVID variants has been published by EnGeneIC in the prestigious journal, Frontiers in Immunology (27th January, 2023).
-
Vera Therapeutics released a 36-week per-protocol analysis of the Phase IIb trial assessing atacicept in IgA nephropathy.
-
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
1/30/2023
Genetic Technologies Limited, a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Quarterly business update for the quarter ended 31 December 2022.
-
Cocrystal Pharma Announces Participation in Virtual Investor Events
1/26/2023
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO and CFO, in the following virtual investment community events.
-
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series
1/26/2023
Onconova Therapeutics, Inc. today announced their participation in the Channelchek Takeaway Series from the J.P.Morgan Healthcare Conference, to be broadcast Thursday, January 26, starting at 10:00 EST.
-
A group of 25 senators, led by Sen. Elizabeth Warren (D-MA), is requesting that HHS Sec. Xavier Becerra exercise march-in rights for Xtandi (enzalutamide), a prostate cancer therapeutic.
-
The FDA's approval of Biogen and Eisai's Leqembi and subsequent decision not to approve Eli Lilly's donanemab have sparked debate anew about the anti-amyloid theory in Alzheimer's.
-
The FDA's Peripheral and Central Nervous System Drugs advisory committee will discuss the merits of Biogen and Ionis's ALS candidate tofersen on March 22nd.
-
Sanofi licensed CytoReason's inflammatory bowel disease model in a multi-million dollar bid to identify new therapies for IBD and Crohn’s and colitis.
-
Editas announced the sale of its iPSC-derived iNK programs to Shoreline Biosciences. Shoreline also licensed Editas' SLEEK technology.
-
The past decade has seen an immuno-oncology revolution, but there is still work to be done. BioSpace looks at innovative research from Nectin Therapeutics, Compugen and Biond Biologics.
-
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
1/16/2023
Eisai Co., Ltd. and Biogen Inc. announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril1 antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency.
-
BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in Japan
1/16/2023
BioArctic AB's partner Eisai announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril[1] antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency.
-
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
1/16/2023
Acurx Pharmaceuticals, Inc. is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023.
-
PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"
1/13/2023
PacBio today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."
-
Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
1/12/2023
Relmada Therapeutics, Inc. today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors.
-
Alto reported positive data from a first-of-its-kind Phase IIb trial of major depressive disorder candidate ALTO-100.